<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-21T04:25:19Z</responseDate><request verb="GetRecord" identifier="oai:macsphere.mcmaster.ca:11375/15318" metadataPrefix="dim">https://prod-ms-be.lib.mcmaster.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:macsphere.mcmaster.ca:11375/15318</identifier><datestamp>2026-09-24T01:47:42Z</datestamp><setSpec>com_11375_271</setSpec><setSpec>col_11375_272</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor" lang="en_US">Wallace, John L.</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author" lang="en_US">Elsheikh, Wagdi K.</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department" lang="en_US">Medical Sciences (Division of Physiology/Pharmacology)</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2014-06-18T21:13:37Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="created" lang="en_US">2013-12-15</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued" lang="en_US">2014-04</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="embargo">2014-12-12</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="embargoset" lang="en_US">2014-12-12</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other" lang="en_US">opendissertations/8628</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other" lang="en_US">9704</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other" lang="en_US">4925588</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/11375/15318</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://doi.org/10.71548/18289</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">&lt;p>Colorectal cancer leads to more than 600,000 deaths worldwide per year. An abundance of research has shown that several non-steroidal anti-inflammatory drugs (NSAIDs) can exert chemotherapeutic and chemo-preventative effects in colorectal cancer patients. It is important to note, that use of many different NSAIDs carries a significant risk for cardiovascular and gastrointestinal (GI) complications. A recently developed group of NSAIDs, which release hydrogen sulfide (H&lt;sub>2&lt;/sub>S), has been shown to have greatly reduced these side effects as compared to conventional NSAIDs. This is likely attributable to the ability of H&lt;sub>2&lt;/sub>S to increase the resistance of the GI mucosa to injury, as well as to accelerate repair of injury when it occurs. Moreover, H&lt;sub>2&lt;/sub>S has been shown to be a vasodilator, and therefore may offset some of the hypertensive effects of NSAIDs.&lt;/p> &lt;p>We assessed the chemotherapeutic actions of two of these newly developed NSAIDs. ATB-346 is an H&lt;sub>2&lt;/sub>S-releasing derivative of naproxen and ATB-352 is an H&lt;sub>2&lt;/sub>S-releasing derivative of ketoprofen. These drugs were tested in the azoxymethane mouse model and in the APC&lt;sup>Min/+ &lt;/sup>mouse model of Colorectal cancer.&lt;/p> &lt;p>In the azoxymethane model of colorectal cancer ATB-346 caused a significant reduction in number aberrant crypt foci (ACF), which are pre-neoplastic lesions used as markers of colorectal cancer. The reduction was superior to naproxen at all doses tested. ATB-352 also caused a significant reduction in the number of ACF, however the reduction was not superior to that produced by ketoprofen. In APC&lt;sup>Min/+ &lt;/sup>mice treated with ATB-346 for 14 days (14.5 mg/kg) we observed a complete inhibition of the formation of colonic polyps/tumours and a 97.5% reduction in total polyp score. Shorter treatment with ATB-346 also produced similar reduction in total polyp score. We found that ATB-346-treated mice had lower levels of b-catenin and cmyc without significant changes in APC or p53 levels. &lt;strong>&lt;/strong&gt;&lt;/p> &lt;p>These results demonstrate ATB-346 can exert superior chemo-preventative effects in mice models of colon cancer while leading to no gastric or intestinal damage.&lt;/p></dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree" lang="en_US">Master of Science (MSc)</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Colorectal Cancer</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">NSAIDs</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Neoplasms</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Gastrointestinal Disease</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Chemo-prevention</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Hydrogen Sulfide</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Digestive System Diseases</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Medical Pharmacology</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Neoplasms</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Pharmaceutics and Drug Design</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Digestive System Diseases</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">CHEMO-PREVENTATIVE EFFECTS OF HYDROGEN SULFIDE-RELEASING NSAIDS IN MURINE COLORECTAL CANCER</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">thesis</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>